Biopharma Industry

Partnering to Enhance Your Drugs Potential: New Targets, New Biomarkers, Deeper Understanding

Partnering with us means going beyond technology and data generation. It means unlocking added value through interpretation of complex immune profiles in dialogue with our leading immunologists, guiding enhanced decision making which has the potential to greatly impact drug development in oncology or infectious diseases.

Our powerful Immune Profiling and Bioinformatics Tools provide the following Key Benefits:

  • Enhance understanding of pharmacodynamics and drug mechanisms of action
  • Enable deeper insight into patient immune response and how it is changed by treatment
  • Identify immune correlates of early efficacy
  • Identify predictive markers of toxicity
  • Identify candidate biomarkers for patient stratification
  • Enable early comparison of potency and immunogenicity of different combination strategies in clinical trials
  • Overcome challenges of typical workflows in the detection of rare event antigen-specific T cell responses delivering high quality reliable data
  • Validate immunogenicity of candidate vaccine antigens
  • Discover new targets for immunotherapy
  • Derive TCR able to recognize relevant targets

 

We provide immunological insights throughout the development process for new immunotherapies and vaccines

 

“I consider immunoScape a strong partner for understanding immune response. I am impressed with the data from their high throughput screening of antigen specificity.”

Dr Mahesh Yadav, Genentech

Academic Research

Driving Translational Research and Pioneering Discoveries

Partnering with us means going beyond technology and data generation. It means unlocking added value through interpretation of complex immune profiles in dialogue with our leading immunologists, guiding enhanced decision making in translational research.

Our powerful Immune Profiling and Bioinformatics Tools provide Key Benefits:

  • Assess biomarker signatures and potential correlations with clinical outcome
  • Discover biomarker signatures associated with adverse clinical events
  • Enable deeper insight into patient immune response and how it is changed by treatment
  • Enable comparison of potency and immunogenicity of different combination strategies in early clinical trials
  • Generate hypotheses for improving clinical management of patients
  • Overcome challenges of typical workflows in the detection of rare event antigen-specific T cell responses delivering high quality reliable data
  • Generate robust and insightful data for high-impact publications

ImmunoScape is a great partner for us. They have excellent technical expertise and feedback outstanding data. I am super impressed with their work and have a fantastic working relationship with the team.

Dr Al Leslie, Principal Investigator, Africa Health Research Institute

COVID-19

ImmunoScape is proud to partner with academic and industry leaders in the fight against COVID-19.  ImmunoScape is currently working with Arcturus Therapeutics and other biopharma companies and major academic institutes.  Our studies include the longitudinal assessment of immune profiles in mild-to-severe COVID-19 patients, characterization of CoV-2-specific T Cells in COVID-19 convalescent donors, and modeling the evolution of the T Cell immune response elicited during vaccination with mRNA-based candidates.

To be most effective against COVID-19, we are conducting a 2-pronged approach at ImmunoScape:

 

Natural COVID-19 infection studies

ImmuoScape is working with renowned research institutions to generate insights into the protective host response against COVID-19, both in convalescent patients and in patients during acute COVID-19 infection, to model the evolution of the immune response during disease progressions.

COVID-19 vaccine assessment studies

ImmunoScape is working with BioPharma companies involved in COVID-19 vaccine development to generate insights into the magnitude and nature of the immune response induced by the COVID-19 vaccine candidates.

Top